Literature DB >> 15743930

Identification of subunit- and antagonist-specific amino acid residues in the N-Methyl-D-aspartate receptor glutamate-binding pocket.

Leo Kinarsky1, Bihua Feng, Donald A Skifter, Richard M Morley, Simon Sherman, David E Jane, Daniel T Monaghan.   

Abstract

The resolved X-ray crystal structures of the glutamate-binding domain (S1/S2 domains) of the GluR2 and NR1 glutamate receptor subunits were used to model the homologous regions of the N-methyl-D-aspartate (NMDA) receptor's NR2 subunits. To test the predictive value of these models, all four stereoisomers of the antagonist 1-(phenanthren-2-carbonyl) piperazine-2,3-dicarboxylic acid (PPDA) were docked into the NR2B glutamate-binding site model. This analysis suggested an affinity order for the PPDA isomers of d-cis > L-cis > L-trans = D-trans and predicted that the 2-position carboxylate group of the cis-PPDA isomers, but not of the trans-PPDA isomers, may be interacting with histidine 486 in NR2B. Consistent with these predictions, cis-PPDA displays a 35-fold higher affinity for NR2B-containing NMDA receptors than trans-PPDA. In addition, mutating NR2B's H486 to phenylalanine decreased cis-PPDA affinity 8-fold but had no effect on trans-PPDA affinity. In contrast, the NR2B H486F mutation increased the affinity of the typical antagonists CGS-19755 [(2R*,4S*)-4-phosphonomethyl-2-piperidine carboxylic acid] and 4-(3-phosphonopropyl) piperidine-2-carboxylic acid. In the NR1-based NR2 models, there were only four subunit-specific amino acid residues exposed to the ligand-binding pocket (and six in the GluR2-based models). These residues are located at the edge of the binding pocket, suggesting that large antagonists may be necessary for subtype specificity. Of these residues, mutational analysis and modeling suggest that A414, R712, and G713 (NR2B numbering) may be especially useful for developing NR2C- and NR2D-selective NMDA receptor antagonists and that residues A414 and T428 may determine subunit variations in agonist affinity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15743930     DOI: 10.1124/jpet.104.082990

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  19 in total

Review 1.  Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators.

Authors:  Daniel T Monaghan; Mark W Irvine; Blaise Mathias Costa; Guangyu Fang; David E Jane
Journal:  Neurochem Int       Date:  2012-01-17       Impact factor: 3.921

Review 2.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

3.  Conantokins derived from the Asprella clade impart conRl-B, an N-methyl d-aspartate receptor antagonist with a unique selectivity profile for NR2B subunits.

Authors:  Konkallu Hanumae Gowd; Tiffany S Han; Vernon Twede; Joanna Gajewiak; Misty D Smith; Maren Watkins; Randall J Platt; Gabriela Toledo; H Steve White; Baldomero M Olivera; Grzegorz Bulaj
Journal:  Biochemistry       Date:  2012-05-30       Impact factor: 3.162

4.  From molecular phylogeny towards differentiating pharmacology for NMDA receptor subtypes.

Authors:  Randall J Platt; Kigen J Curtice; Vernon D Twede; Maren Watkins; Paweł Gruszczyński; Grzegorz Bulaj; Martin P Horvath; Baldomero M Olivera
Journal:  Toxicon       Date:  2014-02-07       Impact factor: 3.033

5.  Piperazine-2,3-dicarboxylic acid derivatives as dual antagonists of NMDA and GluK1-containing kainate receptors.

Authors:  Mark W Irvine; Blaise M Costa; Daniel Dlaboga; Georgia R Culley; Richard Hulse; Caroline L Scholefield; Palmi Atlason; Guangyu Fang; Richard Eaves; Richard Morley; Maria B Mayo-Martin; Mascia Amici; Zuner A Bortolotto; Lucy Donaldson; Graham L Collingridge; Elek Molnár; Daniel T Monaghan; David E Jane
Journal:  J Med Chem       Date:  2011-12-14       Impact factor: 7.446

6.  Structural determinants of agonist efficacy at the glutamate binding site of N-methyl-D-aspartate receptors.

Authors:  Kasper B Hansen; Nami Tajima; Rune Risgaard; Riley E Perszyk; Lars Jørgensen; Katie M Vance; Kevin K Ogden; Rasmus P Clausen; Hiro Furukawa; Stephen F Traynelis
Journal:  Mol Pharmacol       Date:  2013-04-26       Impact factor: 4.436

Review 7.  Novel NMDA receptor modulators: an update.

Authors:  Rose M Santangelo; Timothy M Acker; Sommer S Zimmerman; Brooke M Katzman; Katie L Strong; Stephen F Traynelis; Dennis C Liotta
Journal:  Expert Opin Ther Pat       Date:  2012-09-26       Impact factor: 6.674

8.  N-Hydroxypyrazolyl glycine derivatives as selective N-methyl-D-aspartic acid receptor ligands.

Authors:  Rasmus P Clausen; Caspar Christensen; Kasper B Hansen; Jeremy R Greenwood; Lars Jørgensen; Nicola Micale; Jens Christian Madsen; Birgitte Nielsen; Jan Egebjerg; Hans Bräuner-Osborne; Stephen F Traynelis; Jesper L Kristensen
Journal:  J Med Chem       Date:  2008-06-25       Impact factor: 7.446

9.  Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes.

Authors:  Philip E Chen; Matthew T Geballe; Elyse Katz; Kevin Erreger; Matthew R Livesey; Kate K O'Toole; Phuong Le; C Justin Lee; James P Snyder; Stephen F Traynelis; David J A Wyllie
Journal:  J Physiol       Date:  2007-10-25       Impact factor: 5.182

10.  N-methyl-D-aspartate (NMDA) receptor NR2 subunit selectivity of a series of novel piperazine-2,3-dicarboxylate derivatives: preferential blockade of extrasynaptic NMDA receptors in the rat hippocampal CA3-CA1 synapse.

Authors:  Blaise Mathias Costa; Bihua Feng; Timur S Tsintsadze; Richard M Morley; Mark W Irvine; Vera Tsintsadze; Natasha A Lozovaya; David E Jane; Daniel T Monaghan
Journal:  J Pharmacol Exp Ther       Date:  2009-08-14       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.